Transient Efficacy of Tofacitinib in Alopecia Areata Universalis.
-
Anzengruber F
Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland.
-
Maul JT
Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland.
-
Kamarachev J
Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland.
-
Trüeb RM
Dermatologische Praxis und Haarcenter, Wallisellen, Switzerland.
-
French LE
Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland.
-
Navarini AA
Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland.
Show more…
Published in:
- Case reports in dermatology. - 2016
English
Alopecia areata is a common autoimmune disorder that targets hair follicles. Swarms of lymphocytes surround the basis of the follicles, inducing loss of pigmented terminal hair and subsequently inhibit further hair growth. Depending on the extent of involvement, alopecia areata can be associated with a dramatic reduction of quality of life. Currently, no targeted treatment option is available, and topical immune therapies or immunosuppressive drugs are typically used with mixed success. Recently, several cases of alopecia areata responding to Janus kinase inhibitors were published. Here, we report on a businessman with alopecia areata universalis who was treated with tofacitinib. We observed initial signs of hair regrowth in the same timeframe as previously reported, but efficacy quickly waned again, leading to renewed effluvium. Thus, even though tofacitinib and ruxolitinib are a promising new treatment option, we have yet to learn more about their potential role in each particular patient's individual treatment strategy.
-
Language
-
-
Open access status
-
gold
-
Identifiers
-
-
Persistent URL
-
https://sonar.ch/global/documents/95096
Statistics
Document views: 16
File downloads: